These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 39072721)

  • 1. A Comparative Clinical Pharmacology Analysis of FDA-Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology.
    Ngo HX; Wen YW; Pisupati S; Huang W; Mandlekar S
    Clin Pharmacol Ther; 2024 Nov; 116(5):1198-1206. PubMed ID: 39072721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in covalent warheads for in vivo targeting of endogenous proteins.
    Shindo N; Ojida A
    Bioorg Med Chem; 2021 Oct; 47():116386. PubMed ID: 34509863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs.
    Liu WA; Yu L; Morcos PN; Mercier F; Brennan BJ
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1015-1027. PubMed ID: 32424570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.
    Venkatakrishnan K; Pickard MD; von Moltke LL
    Clin Pharmacokinet; 2010 Nov; 49(11):703-27. PubMed ID: 20923246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.
    Latham BD; Geffert RM; Jackson KD
    Drug Metab Dispos; 2024 May; 52(6):479-492. PubMed ID: 38286637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements.
    Yang J; Tabuchi Y; Katsuki R; Taki M
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets.
    Lee J; Park SB
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.
    Waters NJ
    Br J Clin Pharmacol; 2015 Jun; 79(6):946-58. PubMed ID: 25443889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches to mitigate the risk of serious adverse reactions in covalent drug design.
    Baillie TA
    Expert Opin Drug Discov; 2021 Mar; 16(3):275-287. PubMed ID: 33006907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covalent inhibitors: An ambitious approach for the discovery of newer oncotherapeutics.
    Cheke RS; Kharkar PS
    Drug Dev Res; 2024 Feb; 85(1):e22132. PubMed ID: 38054744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.
    Tibau A; Hwang TJ; Molto C; Avorn J; Kesselheim AS
    JAMA Oncol; 2024 May; 10(5):634-641. PubMed ID: 38573645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012 and 2018.
    Rogers H; Adeniyi O; Ramamoorthy A; Bailey S; Pacanowski M
    Clin Transl Sci; 2021 Mar; 14(2):468-475. PubMed ID: 33278337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions.
    Xiao JJ; Chen JS; Lum BL; Graham RA
    Anticancer Drugs; 2017 Aug; 28(7):677-701. PubMed ID: 28542036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
    Gehringer M; Laufer SA
    J Med Chem; 2019 Jun; 62(12):5673-5724. PubMed ID: 30565923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
    Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
    Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.